Ulrich Tebbe - Concepedia

Author

Ulrich Tebbe

Also Known As

A.A. Schmaltz, D Westermeier, D. Boscher, G Schuler, Hermann Klein, Horst-Eberhard Gerlach, M Kriete, M. Kriete, P. Neumann, Patrizia Torremante

310

Publications

8.7K

Citations

H-Index

Concepts

All Affiliations

Klinikum Lippe Segeberger Kliniken Kerckhoff Klinik Universitätsmedizin Rostock Elisabeth-Krankenhaus Essen

About

Ulrich Tebbe is an author at Klinikum Lippe specializing in medicine, cardiovascular disease, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	62	4.8K
2	Public Health	15	20	2K
3	Health Sciences	2	2	46
4	Biomedical Engineering	2	2	386
5	Diabetes	2	2	113

Ulrich Tebbe

Publications

7.3K

Citations

H-Index

Page 1

	Year	Citations
Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism Nils Kucher, Peter Boekstegers, Oliver J. Müller, Circulation	2013	1.1K
Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation J. Carlsson, Siniša Miketíc, Jürgen Windeler, Journal of the American College of Cardiology Electrophysiological EvaluationCardiovascular DiseaseCardiovascular PharmacologyAtrial FibrillationPersistent Atrial Fibrillation	2003	941
Extent of early ST segment elevation resolution: A simple but strong predictor of outcome in patients with acute myocardial infarction Rolf Schröder, Thomas Brüggemann, Karl Wegscheider, Journal of the American College of Cardiology ThrombosisCardiovascular DiseaseAtherosclerosisStrong PredictorAcute Myocardial Infarction	1994	462
The Na+/H+exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction11This manuscript is dedicated to the memory of Karl-Ludwig Neuhaus (1944–2000). Uwe Zeymer, Harry Suryapranata, J P Monassier, Journal of the American College of Cardiology ThrombosisNa+/h+exchange Inhibitor EniporideCardiovascular DiseaseEarly Reperfusion TherapyMedicine	2001	331
Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator Karl-Ludwig Neuhaus, Werner Feuerer, Susanne Jeep-Tebbe, Journal of the American College of Cardiology ThrombopoiesisThrombosisVenous ThrombosisBlood PlateletPharmacology	1989	299
Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) K. L. Neuhaus, R. von Essen, Ulrich Tebbe, Circulation	1994	283
The Changing Landscape for Stroke Prevention in AF Menno V. Huisman, Kenneth J. Rothman, Miney Paquette, Journal of the American College of Cardiology	2017	276
Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: Retrospective analysis of four german multicenter studies Albrecht Vogt, R. von Essen, Ulrich Tebbe, Journal of the American College of Cardiology ThrombosisVenous ThrombosisCardiovascular DiseaseGerman Multicenter StudiesMyocardial Infarction	1993	264
Intravenous Recombinant Tissue Plasminogen Activator (rt-PA) and Urokinase in Acute Myocardial Infarction: Results of the German Activator Urokinase Study (GAUS) Karl-Ludwig Neuhaus, Ulrich Tebbe, Martin Gottwik, Journal of the American College of Cardiology ThrombosisCardiovascular DiseaseMedicineAtherosclerosisFibrinolysis	1988	214
A prospective placebo-controlled double-blind multicenter trial of intravenous streptokinase in acute myocardial infarction (ISAM): Long-term mortality and morbidity Rolf Schröder, Karl-Ludwig Neuhaus, Alain Leizorovicz, Journal of the American College of Cardiology ThrombosisIntravenous StreptokinaseCardiovascular DiseaseLong-term MortalityPharmacotherapy	1987	158

Page 1